BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15210041)

  • 21. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD; Ewald N
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G
    Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
    Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
    Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
    Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R
    Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
    Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
    Schulze G
    Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum tissue polypeptide specific antigen (TPS) in patients with cervical carcinoma: preliminary report.
    Pattaranutaporn P; Chansilpa Y; Tangkarat S; Tepmongkol P; Sangruchi S; Senapad S
    Anticancer Res; 1997; 17(3C):2309-12. PubMed ID: 9216707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.
    Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H
    Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
    Staib P; Hoffmann M; Schinköthe T
    Clin Chem Lab Med; 2006; 44(1):28-31. PubMed ID: 16375581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
    Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The significance of TU M2-PK tumor marker for lung cancer diagnostics].
    Oremek G; Kukshaĭte R; Sapoutzis N; Ziolkowski P
    Klin Med (Mosk); 2007; 85(7):56-8. PubMed ID: 17882813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma TM2-PK levels in mycosis fungoides patients.
    Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
    Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor M2-PK levels in haematological malignancies.
    Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
    Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
    Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.